Authorized Generics: FTC Study May Get Jumpstart; PhRMA Paper Finds No Harm

The Federal Trade Commission's study on the impact of authorized generics could be enhanced under an amendment to the legislation reauthorizing the FDA's Rx user fee program

More from Archive

More from Pink Sheet